Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2006-11-27
2010-06-29
Anderson, Rebecca L (Department: 1626)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S414000, C514S217040, C514S228200, C514S235200, C514S316000, C514S323000, C540S597000, C544S124000, C544S144000, C546S187000, C546S201000, C548S468000
Reexamination Certificate
active
07745479
ABSTRACT:
The present invention relates to compounds of formula Iwherein R1to R4and G are as defined in the description and claims and pharmaceutically acceptable salts thereof. The compounds are useful for the treatment and/or prevention of diseases which are associated with the modulation of H3 receptors.
REFERENCES:
patent: 4598089 (1986-07-01), Hadvary et al.
patent: 4931463 (1990-06-01), Barbier et al.
patent: 4983746 (1991-01-01), Barbier et al.
patent: 5175186 (1992-12-01), Barbier et al.
patent: 5246960 (1993-09-01), Barbier et al.
patent: 5399720 (1995-03-01), Karpf et al.
patent: 6004996 (1999-12-01), Shah et al.
patent: 7361682 (2008-04-01), McArthur et al.
patent: 7507736 (2009-03-01), Nettekoven et al.
patent: 7538101 (2009-05-01), Nettekoven et al.
patent: 2005/0282864 (2005-12-01), McArthur et al.
patent: 0 189 577 (1989-12-01), None
patent: 0 185 359 (1991-12-01), None
patent: 0 524 495 (1996-10-01), None
patent: 0 443 449 (1997-05-01), None
patent: WO 99/34786 (1999-07-01), None
patent: WO 00/09122 (2000-02-01), None
patent: WO 00/09123 (2000-02-01), None
patent: WO 00/58293 (2000-10-01), None
patent: WO 2005/123716 (2005-12-01), None
Burks 1994 in Johnson L.R. ed., Physiology of the Gastrointestinal Tract, Raven Press, NY, pp. 211-242.
Leurs et al., Br J. Pharmacol. 1991, 102, pp. 179-185.
Raithel et al., Int. Arch. Allergy Immunol. 1995, 108, 127-133.
Panula et al., Proc. Natl. Acad. Sci. USA 1984, 81, 2572-2576.
Inagaki et al., J. Comp. Neurol 1988, 273, 283-300.
Arrang et al., Nature 1983, 302, 832-837.
Arrang et al., Neuroscience 1987, 23, 149-157.
Clapham & Kilpatrik, Br. J. Pharmacol. 1982, 107, 919-923.
Blandina et al. in The Histamine H3 Receptor (Leurs RL and Timmermann H eds, 1998, pp. 27-40, Elsevier, Amsterdam, The Netherlands.
Masaki et al; Endocrinol. 2003, 144, 2741-2748.
Hancock et al., European J. of Pharmacol. 2004, 487, 183-197.
Timmermann, J. Med. Chem. 1990, 33, 4-11.
Mederski, W. W. K. R.; Lefort, M.; Germann, M. Kux, D. Tetrahedron 1999 55 12757.
Watanabe, M; Nishiyama, M.; Yamamoto, T.; Koie, Y, Tetrahedron Letters 2000, 41, 481.
Old, D. W.; Harris, M. C.; Buchwald, S. L 2000 2 10 1403.
Klapars, A.; Antilla, J. C.; Huang, X.; Buchwald, S. L. J. Am. Chem. Soc. 2001 123 7727.
Takahashi, K, Tokita, S., Kotani, H. (2003) J. Pharmacol. Exp. Therapeutics 307, 213-218.
Cheng, Y, Prusoff, WH (1973) Biochem Pharmacol 22, 3099-3108.
Venable Jennifer, D., et al., Journal of Medicinal Chemistry, vol. 48, No. 26, pp. 8289-8298 (2005), XP002433085.
Nettekoven Matthias
Plancher Jean-Marc
Richter Hans
Roche Olivier
Runtz-Schmitt Valerie
Anderson Rebecca L
Hoffmann-La Roche Inc.
Johnston George W.
Megerditchian Samuel H.
Nolan Jason M
LandOfFree
1,5-substituted indol-2-yl amide derivatives does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with 1,5-substituted indol-2-yl amide derivatives, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and 1,5-substituted indol-2-yl amide derivatives will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4250874